Pooled RNAi Screens to Identify Synthetic Lethals in ERBB2+ Breast Cancer CellsWednesday, 18 September 2013 at 10:00  Add to Calendar ▼2013-09-18 10:00:002013-09-18 11:00:00Europe/LondonPooled RNAi Screens to Identify Synthetic Lethals in ERBB2+ Breast Cancer CellsAcademic Screening Workshop 2013 in Baltimore, MA, USABaltimore, MA, USASELECTBIOenquiries@selectbiosciences.comERBB2 is a receptor tyrosine kinase amplified and overexpressed in 15-20% of breast tumors (ERBB2+ tumors) and is associated with a poor prognosis. Current therapies targeting ERBB2, have resulted in improvements in survival but innate and acquired resistance have increasingly occurred. By combining genome-wide RNAi loss-of-function screens with system biology interactome models we have recently found that the JAK/STAT3 pathway is activated in ERBB2+ breast tumors. Activation of STAT3 was found to be essential to maintain the homeostasis of these tumors as genetic and pharmacological inhibition of this pathway strongly compromised their viability. |
Add to Calendar ▼2013-09-17 00:00:002013-09-18 00:00:00Europe/LondonAcademic Screening Workshop 2013Academic Screening Workshop 2013 in Baltimore, MA, USABaltimore, MA, USASELECTBIOenquiries@selectbiosciences.com
